Top

Published in:

Open Access 01-12-2017 | Short report

Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses

Authors: Pirooz Zareie, Bronwen Connor, Anne Camille La Flamme

Published in: Journal of Neuroinflammation | Issue 1/2017

Abstract

Atypical antipsychotic agents, such as clozapine, are used for treating psychosis and depression and have recently been found to modulate neuroinflammation. We have shown previously that treatment of mice with the atypical antipsychotic agents, clozapine or risperidone, attenuates disease severity in experimental autoimmune encephalomyelitis (EAE); however, the mechanism by which they are protective is unknown. In this study, we investigated the effects of clozapine on CD4⁺ T cell responses and found that clozapine did not significantly affect the expansion of myelin-specific T cells, their differentiation into pathogenic subsets, or their encephalitogenic capacity to induce EAE. Interestingly, although clozapine enhanced differentiation of regulatory T (Treg) cells, in vivo neutralization of Tregs indicated that Tregs were not responsible for the protective effects of clozapine during the induction and effector phase of EAE. Taken together, our studies indicate that clozapine does not mediate its protective effects by directly altering CD4 T cells.

Available only for authorised users

Wu GF, Alvarez E. The immuno-pathophysiology of multiple sclerosis. Neurol Clin. 2011;29(2):257–78.CrossRefPubMedPubMedCentral

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.CrossRefPubMed

Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–93.CrossRefPubMed

Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14.CrossRefPubMedPubMedCentral

Montalban X, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376:209–220.CrossRefPubMed

Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34.CrossRefPubMed

Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):11–38.CrossRefPubMed

Potvin S, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801–8.CrossRefPubMed

Sacre S, et al. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010;62(3):683–93.CrossRefPubMed

10.

O’Sullivan D, et al. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. PLoS One. 2014;9(8):e104430.CrossRefPubMedPubMedCentral

11.

Mei F, et al. Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. PLoS ONE. 2012;7(8):e42746.CrossRefPubMedPubMedCentral

12.

Ribeiro BM, et al. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr Res. 2013;151(1–3):12–9.CrossRefPubMed

13.

Miller BJ, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71.CrossRefPubMedPubMedCentral

14.

Green LK, et al. Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis. Mult Scler J Exp Trans Clin. 2017;1–13. do:10.1177/2055217317698724.

15.

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.CrossRefPubMed

16.

O’Sullivan D, et al. Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration. Immunol Cell Biol. 2013;91(9):583–92.CrossRefPubMed

17.

Koutrolos M, et al. Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS. Acta Neuropathol Commun. 2014;2:163.CrossRefPubMedPubMedCentral

18.

Chu C-Q, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated Cd4 T cell population in interferon γ–deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med. 2000;192(1):123–8.CrossRefPubMedPubMedCentral

19.

Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol. 2008;8(4):460–71.CrossRefPubMed

20.

Sanders VM, et al. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol. 1997;158(9):4200–10.PubMed

21.

Cua DJ, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744–8.CrossRefPubMed

22.

Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32.CrossRefPubMedPubMedCentral

23.

Al-Amin MM, Nasir Uddin MM, Mahmud Reza H. Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci. 2013;11(3):144–51.CrossRefPubMedPubMedCentral

24.

Szabo SJ, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100(6):655–69.CrossRefPubMed

25.

Ivanov II, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–33.CrossRefPubMed

26.

Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6(4):331–7.CrossRefPubMed

27.

Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A. 2005;102(48):17418–23.CrossRefPubMedPubMedCentral

28.

Koutrolos M, et al. Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS. Acta Neuropathol Commun. 2014;2(1):1–7.CrossRef

29.

Lu LX, et al. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao. 2004;24(11):1251–4.PubMed

30.

Hu X, et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J Neuroimmune Pharmacol. 2012;7(1):187–201.CrossRefPubMed

31.

Chen M-L, et al. Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. Immunol Lett. 2011;140(1–2):81–91.CrossRefPubMed

32.

Panariello F, et al. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. J Cell Physiol. 2012;227(4):1485–92.CrossRefPubMed

33.

Kang UG, et al. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 2004;560(1–3):115–9.CrossRefPubMed

34.

Schmid CL, et al. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a [beta]arrestin2-independent activation of Akt. Neuropsychopharmacology. 2014;39(8):1902–13.CrossRefPubMedPubMedCentral

35.

Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.CrossRefPubMedPubMedCentral

36.

Kopf H, et al. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol. 2007;7(13):1819–24.CrossRefPubMedPubMedCentral

37.

Delgoffe GM, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009;30(6):832–44.CrossRefPubMedPubMedCentral

38.

Ajami B, et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14(9):1142–9.CrossRefPubMed

39.

Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7:185–217.CrossRefPubMed

40.

Mishra MK, Yong VW. Myeloid cells—targets of medication in multiple sclerosis. Nat Rev Neurol. 2016;12(9):539–51.CrossRefPubMed

Title: Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses
Authors: Pirooz Zareie
Bronwen Connor
Anne Camille La Flamme
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2017
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-017-0842-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder

Heparanase promotes neuroinflammatory response during subarachnoid hemorrhage in rats

Erratum to: The role of PPAR activation during the systemic response to brain injury

Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury

Absence of system xc − on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis

Complex regulation of neutrophil-derived MMP-9 secretion in central nervous system tuberculosis